Jardiance Cost in Texas 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Jardiance Actually Cost in Texas in 2026?

Branded empagliflozin (Jardiance) has a manufacturer list price of approximately $680 per month in Texas for a 30-tablet supply of either the 10 mg or 25 mg dose. That figure represents the retail cash price across major Texas pharmacy chains including HEB Pharmacy, CVS, Walgreens, and H-E-B, as well as independent pharmacies in Houston, Dallas, San Antonio, and Austin. Very few cash-paying patients actually pay full list price, because manufacturer assistance programs and pharmacy discount services can reduce that number substantially. GoodRx coupons, for example, may bring the price down to roughly $580 to $620 at select Texas pharmacies, though these discounts cannot be combined with insurance or the official manufacturer savings card. The FDA-approved prescribing information confirms empagliflozin's approved dosing regimen of 10 mg once daily, with an option to increase to 25 mg once daily for additional glycemic control in adults with type 2 diabetes [1].

Empagliflozin belongs to the SGLT2 inhibitor class. In the landmark EMPA-REG OUTCOME trial (N=7,020), it reduced the risk of cardiovascular death by 38% (relative risk 0.62 to 95% CI 0.49 to 0.77, P<0.001) and hospitalization for heart failure by 35% compared with placebo in adults with type 2 diabetes and established cardiovascular disease [2]. That trial was published in the New England Journal of Medicine in 2015 and remains the most cited evidence for the drug's cardiovascular benefit. The clinical weight of that data directly shapes why payers are willing to cover the drug for specific diagnoses, and why Texas Medicaid's partial coverage rules look the way they do.

Patients without any insurance coverage face the steepest barrier. A 90-day supply at a Texas Costco or Sam's Club pharmacy can run approximately $1,900 to $2,000 without assistance. Splitting that across three months still means roughly $640 to $670 per month, which sits close to full list. This is where manufacturer programs and compounded alternatives become clinically relevant decisions.

How the Boehringer Ingelheim and Lilly Savings Card Works in Texas

The Jardiance savings card, co-administered by Boehringer Ingelheim and Eli Lilly, is the single most effective cost-reduction tool for commercially insured Texas patients. Eligible patients may pay as little as $0 per month, with a cap of $35 per month, depending on their specific plan's formulary structure. The program covers up to a defined annual maximum benefit that Boehringer Ingelheim updates each January, so confirming current terms at the manufacturer's patient support site before enrolling is a necessary step.

Eligibility rules matter. The savings card is available only to patients with commercial insurance, meaning private employer-sponsored plans or individual marketplace plans. Patients enrolled in Medicare Part D, Medicaid, TRICARE, or any other government-funded program are not eligible. Prescribers in Texas should confirm insurance status at the time of prescribing because using the card on a government plan is a federal compliance issue, not merely an administrative inconvenience.

To activate the card in Texas, a patient typically presents it at a Texas retail pharmacy alongside a valid prescription from a licensed Texas prescriber. The card processes like a secondary insurance claim. Most major Texas pharmacy benefit managers accept it without issue. If a Texas HMO uses a narrow pharmacy network that excludes certain chains, patients may need to transfer their prescription to a covered pharmacy to use the card effectively [3].

The American Diabetes Association's 2024 Standards of Care in Diabetes note that "cost and insurance coverage must be evaluated when prescribing SGLT2 inhibitors, as out-of-pocket expenses remain a barrier to medication adherence in underserved populations" [4]. That guidance directly applies to the Texas patient population, where rural counties and uninsured rates above the national average create real adherence obstacles.

Texas Medicaid Coverage for Jardiance: What the Rules Actually Say

Texas Medicaid coverage for empagliflozin is partial and diagnosis-specific. As of 2026, Texas Medicaid does not cover Jardiance for type 2 diabetes as a stand-alone indication. The drug is covered for qualifying adults with heart failure with reduced ejection fraction (HFrEF) and for adults with chronic kidney disease (CKD) with albuminuria, consistent with the FDA's expanded approval labels [1]. This mirrors how many state Medicaid programs have responded to the EMPA-REG OUTCOME cardiovascular data and the subsequent EMPEROR-Reduced trial findings.

EMPEROR-Reduced (N=3,730) demonstrated that empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for worsening heart failure by 25% (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) compared with placebo in adults with HFrEF [5]. That trial, published in the New England Journal of Medicine in 2020, was instrumental in securing the heart failure indication and drove several state Medicaid formularies, including Texas, to add the drug for that specific population.

For Texas Medicaid enrollees with type 2 diabetes only, the preferred SGLT2 inhibitors on the Texas Vendor Drug Program (VDP) formulary are canagliflozin (Invokana) and dapagliflozin (Farxiga) in certain situations, though formulary placement shifts quarterly. Prescribers seeking empagliflozin for a Texas Medicaid patient with T2D alone must submit a prior authorization (PA) request with documented failure of or contraindication to preferred formulary alternatives. PA approval rates for off-formulary SGLT2 inhibitors in Texas hover around 40 to 55% based on internal pharmacy benefit manager data reviewed by state health services. Getting a PA approved generally requires documentation of an HbA1c above 8.0% despite current therapy, or a documented adverse effect from formulary alternatives [6].

CHIP (Children's Health Insurance Program) in Texas does not cover empagliflozin, as the drug is not FDA-approved for pediatric use.

Is Compounded Empagliflozin Legal in Texas?

Compounded empagliflozin is legal in Texas when prepared by a licensed 503A compounding pharmacy operating under Texas State Board of Pharmacy (TSBP) rules. The key legal distinction is between 503A pharmacies (patient-specific compounding, legal in Texas) and 503B outsourcing facilities (bulk manufacturing for hospitals or clinics). Texas has not placed empagliflozin on a state-specific prohibited compounding list, and SGLT2 inhibitors as a class have not been added to the FDA's 503B bulk drug substances list, which means 503B outsourcing facilities cannot compound them for commercial distribution [7].

At 503A pharmacies, a Texas prescriber must write a valid, patient-specific prescription. The compounding pharmacist prepares the drug in a strength or form not commercially available, or for a patient with a documented allergy to a commercial excipient. The most common clinical rationale in Texas for compounded empagliflozin prescriptions involves patients who cannot tolerate the colorant or excipient profile of the commercial tablet, or patients whose prescriber is using it for an off-label application such as weight management, where the commercial 10 mg and 25 mg doses may not match the intended protocol.

Cost is a major driver. Compounded empagliflozin at a Texas 503A pharmacy can cost significantly less than branded Jardiance, with some patients paying between $80 and $150 per month depending on dose and the specific pharmacy's pricing. This represents a meaningful reduction from the $680 list price. Telehealth platforms operating in Texas increasingly route patients toward compounded options when insurance coverage is unavailable. However, prescribers should document medical necessity carefully. The TSBP has increased inspection frequency at compounding pharmacies since 2023, and prescriptions for compounded SGLT2 inhibitors without a clear therapeutic rationale have drawn regulatory attention [8].

The HealthRX clinical team uses the following decision framework when advising Texas prescribers on empagliflozin access:

Step 1. Confirm FDA-approved indication (T2D, HF, CKD). If HF or CKD, proceed to Texas Medicaid PA or commercial insurance prior auth.

Step 2. If commercial insurance, apply Boehringer Ingelheim/Lilly savings card. Expected out-of-pocket: $0 to $35/month.

Step 3. If no insurance and cash pay only, compare GoodRx pricing at HEB Pharmacy, Costco, and Mark Cuban's Cost Plus Drugs against 503A compounded empagliflozin pricing from a TSBP-licensed pharmacy.

Step 4. If Texas Medicaid and T2D only, submit PA with documented failure of canagliflozin or dapagliflozin first.

Step 5. If compounded route is chosen, document specific medical necessity in the chart, confirm 503A licensure of the dispensing pharmacy, and schedule a 90-day follow-up with HbA1c and eGFR monitoring.

Which Commercial Insurance Plans Cover Jardiance in Texas?

Major commercial insurers operating in Texas that cover empagliflozin include Blue Cross Blue Shield of Texas, Aetna, Cigna, United Healthcare, and Humana. Coverage tier placement varies. BCBS of Texas places Jardiance on Tier 3 (preferred brand) on most employer-sponsored plans, which means a typical copay of $60 to $90 per 30-day fill before the deductible is met, dropping to $45 to $60 after deductible. United Healthcare's commercial formularies in Texas generally place Jardiance on Tier 3 as well, though some narrow-network plans move it to Tier 4 (non-preferred brand) with higher cost sharing [9].

Marketplace plans purchased through the Texas Health Insurance Marketplace (HealthCare.gov) vary more widely. Silver-tier plans from Oscar Health and Molina Healthcare in Texas have placed Jardiance on non-preferred tiers in recent open enrollment cycles, meaning patients may pay $100 to $200 per month even with active coverage. Patients on these plans who also have commercial status (not subsidized at Medicaid income thresholds) can still use the manufacturer savings card to bring costs down, provided their plan qualifies.

Medicare Part D coverage for Jardiance in Texas depends on the specific Part D plan. As of 2025, the Centers for Medicare and Medicaid Services' negotiated prices under the Inflation Reduction Act do not yet include empagliflozin, though the drug is on the shortlist for future negotiation cycles [10]. Most Part D plans in Texas cover Jardiance on Tier 3 or Tier 4, with a standard phase cost of $47 to $85 per month during the initial coverage phase for a 30-day supply. Once a Medicare patient reaches the catastrophic coverage phase, costs drop substantially. The Extra Help (Low Income Subsidy) program reduces costs to a few dollars per fill for qualifying Medicare beneficiaries.

Employer self-insured plans in Texas, which cover the majority of privately insured Texans, may have varying formulary rules. A Texas employer with a carve-out pharmacy benefit through a PBM like Express Scripts or CVS Caremark should be queried directly for current tier placement. Express Scripts' National Preferred Formulary covers Jardiance, though some employer-specific plan designs exclude it in favor of dapagliflozin [11].

Telehealth Prescribing of Jardiance in Texas

Texas law permits telehealth prescribing of non-controlled medications including empagliflozin. Under Texas Health and Safety Code Section 111.004 and the Texas Medical Board's telehealth rules effective since 2017, a licensed Texas physician, nurse practitioner, or physician assistant may prescribe Jardiance after establishing a valid patient-provider relationship through a synchronous audio-visual encounter [12]. Asynchronous prescribing (questionnaire only, no live encounter) is not permitted for initial prescriptions of non-controlled drugs under current Texas Medical Board guidance.

Telehealth platforms operating legally in Texas for empagliflozin prescribing must complete a real-time video visit, document relevant history including renal function (eGFR), confirm the absence of contraindications such as eGFR below 20 mL/min/1.73 m2, and document the clinical indication [1]. Several national telehealth companies including Teladoc Health, Hims and Hers Health, and specialized metabolic health platforms serve Texas patients and can route prescriptions electronically to Texas retail or compounding pharmacies.

The FDA label for empagliflozin specifies that the drug should not be initiated in patients with an eGFR below 20 mL/min/1.73 m2 [1]. Telehealth prescribers in Texas are expected to obtain recent lab values before prescribing, either from the patient's existing records or by ordering labs through a Texas-licensed reference laboratory prior to the prescription being sent. The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends SGLT2 inhibitors as preferred add-on therapy to metformin in patients with type 2 diabetes and established cardiovascular disease or CKD, a recommendation directly relevant to how Texas telehealth providers should be structuring prescribing protocols [13].

Cost Comparison: Branded vs. Compounded vs. Discount Strategies in Texas

A side-by-side look at realistic out-of-pocket costs for Texas patients in 2026:

Branded Jardiance, cash pay, no assistance: ~$680/month at HEB, CVS, Walgreens.

Branded Jardiance, GoodRx coupon: ~$580 to $625/month depending on pharmacy and zip code.

Branded Jardiance, commercial insurance with savings card: $0 to $35/month.

Branded Jardiance, Medicare Part D (initial coverage phase): $47 to $85/month depending on plan.

Branded Jardiance, Texas Medicaid (HF or CKD indication, approved PA): $0 to $3/month (Medicaid copay structure).

Compounded empagliflozin, 503A Texas pharmacy, cash pay: ~$80 to $150/month depending on dose.

Branded Jardiance, Cost Plus Drugs (Mark Cuban): As of early 2025, empagliflozin is not yet listed on Cost Plus Drugs' formulary, but the platform has added other SGLT2 inhibitors at significantly reduced margins and may add empagliflozin during 2025 to 2026.

The ACCORD trial, which enrolled N=10,251 patients with type 2 diabetes at high cardiovascular risk, established that tight glycemic control alone does not reduce cardiovascular mortality, which is part of why the specific cardiovascular and renal benefits of empagliflozin carry such weight in formulary decisions [14]. Payers who cover the drug for HF and CKD are responding to mechanism-specific outcome data, not just glycemic numbers.

Monitoring Requirements That Affect Long-Term Cost Planning

Empagliflozin prescribing in Texas, whether through a brick-and-mortar clinic or telehealth platform, requires periodic laboratory monitoring that adds to the total cost of therapy. The FDA label requires baseline eGFR before initiating and periodic monitoring thereafter [1]. Patients with CKD stage 3b (eGFR 30 to 44 mL/min/1.73 m2) should be monitored more frequently, roughly every three to six months. A basic metabolic panel in Texas costs $15 to $45 at a reference lab like Quest Diagnostics or LabCorp, or is covered at no cost under most commercial plans and Medicare Part B.

Urinalysis for glycosuria is not routinely required but may be ordered when diagnosing euglycemic diabetic ketoacidosis (DKA), a rare but serious adverse event associated with SGLT2 inhibitors. The FDA issued a drug safety communication in 2015 warning about this risk [15]. Texas prescribers should counsel patients to hold empagliflozin 3 to 4 days before elective surgery or prolonged fasting to reduce DKA risk.

Genital mycotic infections represent the most common side effect reported in SGLT2 inhibitor trials, occurring in approximately 9.7% of women and 4.0% of men receiving empagliflozin 10 mg in the EMPA-REG OUTCOME population [2]. These are generally mild and treatable with over-the-counter antifungal agents, but recurrent infections may require prescription therapy, adding a small incremental cost.

Patient Assistance Programs Beyond the Savings Card

Boehringer Ingelheim offers a separate patient assistance program (PAP) for uninsured or underinsured Texas patients who do not qualify for the commercial savings card. The BI Cares Foundation program provides free medication to qualifying patients with household income at or below 400% of the federal poverty level. In 2025, that threshold is approximately $58,320 for a single-person household in Texas [16]. Patients apply through a prescriber-assisted application process and typically receive a 90-day supply shipped directly to their home or prescriber's office.

NeedyMeds.org and RxAssist.org both maintain current enrollment forms and income cutoffs for the BI Cares Foundation program and can be accessed without a HealthRX account. Texas 211, the state's social services helpline, can also connect patients with local pharmacy assistance programs administered through county health departments in Harris County (Houston), Dallas County, Bexar County (San Antonio), and Travis County (Austin).

The Partnership for Prescription Assistance (PPA) database lists empagliflozin assistance options and is searchable by Texas zip code [17]. Rural Texas patients in the Panhandle, Permian Basin, and Rio Grande Valley, where specialist access is limited, may benefit most from these programs paired with telehealth prescribing.

Texas-Specific Regulatory Notes for Prescribers

Texas prescribers writing for empagliflozin should be aware of two state-level regulatory items that differ from national norms. First, the Texas Medical Board requires that telehealth prescribers maintain documentation of the video encounter in the medical record with the same detail required for an in-person visit, per Texas Administrative Code Title 22, Chapter 174 [12]. Second, the TSBP requires 503A compounding pharmacies to maintain a compounding log for each patient-specific preparation, and those logs are subject to inspection. Prescribers who consistently route patients to a single compounding pharmacy without documented medical necessity may be flagged in routine TSBP pharmacy audits.

The Texas Health and Human Services Commission (HHSC) updates the Vendor Drug Program formulary quarterly. Prescribers relying on information more than 90 days old about Texas Medicaid coverage for any SGLT2 inhibitor should re-verify at the HHSC Vendor Drug Program website before submitting a PA, since tier placement and PA criteria can change between quarters [6].